Skip to content

Ayahuasca: all studies

Page 113 of 167: studies 1,121 to 1,130 of 1,663, newest first. Back to the ayahuasca overview

Research

Impact of CYP2D6 Polymorphisms on the Pharmacokinetics of N,N-Dimethyltryptamine and Harmine via PBPK Modeling and Simulation

Future Pharmacology June 23, 2026 Gabriella de Souza Gomes Ribeiro, Pieter Annaert, Frederico Severino Martins et al.

Background/Objectives: In this study, we present an analysis of ayahuasca, a psychedelic preparation containing N,N-dimethyltryptamine (DMT) and β-carbolines, such as harmine (HRM), a reversible monoamine oxidase A (MAO-A) inhibitor that enables the oral bioavailability of DMT. CYP2D6 is a highly polymorphic enzyme associated with interindividual variability in drug exposure, but its influence...

DOI: 10.3390/futurepharmacol6030034 (opens in new tab) Harmine Pharmacokinetics Cmax Cyp2d6 +5

Estudios psicodélicos en Ecuador: Una breve historia (siglos XIX–XXI)

June 10, 2026 Adrián David Guerra-Layana

En este artículo presentamos aportes de viajeros, investigadores (antropólogos, médicos, psicólogos, químicos, sociólogos), así como sabios ancestrales, todos ellos, exploradores del ámbito de las plantas maestras en Ecuador, país creado en 1830 y ubicado en la región noroccidental de América del Sur, con una población de 18,14 millones de habitantes. Ecuador resalta por su diversidad...

Classic Psychedelics for Chronic Pain: A Critical Review of the Literature and Practical Advice for Clinicians.

Drugs June 4, 2026 Kevin F. Boehnke, Niloufar Pouyan, Jacob S. Aday

Chronic pain is common, costly, and for many, remains inadequately treated by existing pharmacologic and non-pharmacologic approaches. In parallel with growing dissatisfaction with conventional therapies, classic serotonergic psychedelics, such as psilocybin, lysergic acid diethylamide (LSD), ayahuasca, N,N-dimethyltryptamine (DMT), and mescaline, administered alone or within...

Prolonged Grief Symptom Outcomes During At-Home Ketamine-Assisted Therapy: A Real-World Retrospective Analysis of 503 Adults

Research Square June 2, 2026 Davis Carter, Ian Reardon, Jack Swain et al. preprint

Abstract Background Prolonged grief disorder (PGD) is a clinically distinguishable bereavement-related condition characterized by persistent yearning, identity disruption, and impaired functioning, formalized in DSM-5-TR and ICD-11 (6L72) and empirically distinguishable from but frequently co-occurring with major depressive disorder. Approximately 7 to 10 percent of bereaved adults meet...

Psychedelic Renaissance: A New Paradigm in Mental Health

European Psychiatry June 1, 2026 A. M. Matas Ochoa, A. R. Quiroga, I. D. Sacristán

Introduction Psychedelics are hallucinogenic agents that are awakening scientific interest in recent years, especially in the field of mental health. Psychedelics induce non-ordinary states of consciousness and alterations in the emotions and in cognition and could be beneficial in treating some mental illness. Objectives The objective of the poster is to expand knowledge about emerging...

The therapeutic potential of psychedelic drugs: past, present, and future

European Psychiatry June 1, 2026 D. Nutt

Abstract The last decade has seen a remarkable resurgence of interest in psychedelic drugs such as psilocybin (from magic mushrooms) LSD and DMT (dimethyl tryptamine – the active ingredient of ayahuasca). This has been driven by the discovery that these psychedelics all act agonists of 5-HT2A receptors plus human imaging studies that reveal this action leads to profound alterations in brain...

Global increases in brain glucose metabolism following acute N,N-dimethyltryptamine and harmine administration in healthy volunteers: A randomised [ 18 F]FDG-PET study

Universität Zürich, ZORA June 1, 2026 Klemens Egger, Robert Bozsak, Helena Aicher et al.

Classical psychedelics such as N,N -dimethyltryptamine (DMT) modulate consciousness via serotonergic receptor agonism, and are increasingly investigated for their psychotherapeutic potential. When combined with the monoamine oxidase A (MAO-A) inhibitor harmine—mimicking the pharmacological profile of ayahuasca—oral DMT induces a psychedelic experience lasting 4–5 h. While some neuroimaging...

DOI: 10.5167/uzh-434709 (opens in new tab) Harmine Placebo Neuroimaging Metabolite +9

Global increases in brain glucose metabolism following acute N,N-dimethyltryptamine and harmine administration in healthy volunteers: A randomised [18F]FDG-PET study.

Journal of Cerebral Blood Flow & Metabolism June 1, 2026 Klemens Egger, Robert Bozsak, Helena Aicher et al.

Classical psychedelics such as N,N-dimethyltryptamine (DMT) modulate consciousness via serotonergic receptor agonism, and are increasingly investigated for their psychotherapeutic potential. When combined with the monoamine oxidase A (MAO-A) inhibitor harmine-mimicking the pharmacological profile of ayahuasca-oral DMT induces a psychedelic experience lasting 4-5 h. While some neuroimaging...

Classic psychedelics and personality: An updated systematic review.

Journal of Psychopharmacology May 31, 2026 Anna Beatriz Vicentini, Caio César De Paula, José Augusto Silva Reis et al.

The impact of classic psychedelics (5-HT2A receptor agonists) on personality traits has been studied for decades, and it has been hypothesized that the mechanisms underlying these changes are linked to agonism at cortical serotonergic 5-HT2A receptors. However, research results are contradictory. Therefore, the present paper aims to systematically evaluate the effects of psychedelics on...

DOI: 10.1177/02698811261449386 (opens in new tab) Full text (opens in new tab) 5-ht2a receptor agonists Classic psychedelics Personality traits Systematic review

Psicodélicos no tratamento de transtornos psiquiátricos: Evidências clínicas e desafios éticos

Journal of Medical and Biosciences Research. May 30, 2026 Mickail Ivo Souza, Samuel Cândido Freres, Bruna Aparecida Alves Villafranca et al.

Os transtornos psiquiátricos representam importante problema de saúde pública mundial, frequentemente associados a elevada morbidade, incapacidade funcional e impacto significativo na qualidade de vida. Apesar dos avanços terapêuticos disponíveis, muitos pacientes permanecem refratários aos tratamentos convencionais, estimulando a busca por novas abordagens terapêuticas. Nesse contexto, os...

DOI: 10.70164/jmbr.v3i3.1228 (opens in new tab) Anxiety Vulnerability computing Medline Depression economics +3